Orrin Troum, MD
Rheumatology · Santa Monica, CANPI 1821032608
Payments from drug & device makers
Across 3,636 payments — averaging $1888.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2.7M
- Novartis$2.2M
- AbbVie$735K
- E.r. Squibb & Sons, L.L.C.$479K
- Janssen Research & Development, LLC$162K
- Lilly USA, LLC$124K
- plus $482K from 54 others
Across 3 payments — averaging $903.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$1K
- Pfizer$1K
What the payments were for
- Consulting fees$232,65213%
- Speaking & faculty fees$1,264,34472%
- Travel & lodging$193,10811%
- Food & beverage$74,2224%
- Education$3560%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,865,127 in reported general payments places this provider in the 95th percentile of 808 rheumatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StrensiqAsfotase Alfa | 12 | $1,675,363 |
| RinvoqUpadacitinib | 95 | $767,400 |
| Humira(Cf) PenAdalimumab | 72 | $478,549 |
| Enbrel SureclickEtanercept | 52 | $456,017 |
| Enbrel MiniEtanercept | 26 | $193,077 |
| SimponiGolimumab | 21 | $164,509 |
| Bimzelx AutoinjectorBimekizumab-Bkzx | 11 | $158,885 |
| OrenciaAbatacept | 21 | $158,511 |
| KevzaraSarilumab | 33 | $149,322 |
| OtezlaApremilast | 20 | $96,770 |
| Humira(Cf)Adalimumab | 13 | $86,001 |
| XeljanzTofacitinib Citrate | 11 | $82,976 |
| TymlosAbaloparatide | 27 | $72,770 |
| ProliaDenosumab | 36 | $61,563 |
| Teriparatide | 12 | $31,852 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaStrensiq | $1,999 | $1,675,36312 claims |
| AbbVieRinvoq, Humira(Cf) | $735,165 | $853,401108 claims |
| Johnson & JohnsonSimponi | $8,939 | $164,50921 claims |
| E.r. Squibb & Sons, L.L.C.Orencia | $478,594 | $158,51121 claims |
| AmgenOtezla, Prolia | $2,684,859 | $158,33356 claims |
| SanofiKevzara | $110,409 | $149,32233 claims |
| PfizerXeljanz | $61,114 | $82,97611 claims |
| Radius Health, Inc.Tymlos | $526 | $72,77027 claims |
| Alvogen IncTeriparatide | $116 | $31,85212 claims |
| Medexus Pharma, Inc.Rasuvo | $150 | $31,65947 claims |
| Antares Pharma, Inc.Otrexup | $379 | $15,00111 claims |
| Redhill Biopharma Inc.Movantik | $171 | $13,13032 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 808 rheumatology providers in California.
Other rheumatology in Santa Monica
- Amro BalkiSanta Monica$465K
- Samy MetyasCovina$12.9M
- Christine ThaiHuntington Beach$8.5M
- Tien-I SuWhittier$8.4M
- Eric LeeUpland$6.9M
- Shirley PangFullerton$5.7M
- William RobinsonStanford$5.1M
- Dan laTujunga$5.1M
- Christina Charles-SchoemanLos Angeles$4.8M
- Suneet GrewalWest Hollywood$3.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.